


REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claim 10 was amended to correct a typographical error. Support for the amendment may be found in the specification at pages 5, 13, 14, 16, 18, and 19. Claim 32 was amended to correct a typographical error. Support for the amendment may be found in the specification at pages 5 and 13. Claims 15, 16, and 17 have been amended for clarification to include compound names instead of example numbers. Support for the amendment to claim 15 may be found on pages 52 – 185. Support for the amendment to claim 16 may be found on pages 98 – 414. Support for the amendment to claim 17 may be found on pages 64 – 185. Claims 19, 20, 25 and 28 have been amended to remove multiple dependencies. Claims 33 - 40 have been added. Support for new claim 33 may be found in Example 101 on page 115. Support for new claim 34 may be found in Example 288 on page 205. Support for new claims 35 – 40 may be found in the specification at pages 30 - 37. Claims 1 – 21, and 25 - 40 are pending in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for consideration. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: August 11, 2006



Karen L. Prus

Attorney of Record, Reg. No 39,337

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988